Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Press Releases
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
Real-time Euronext Paris  -  03:15 2022-10-03 am EDT
0.5890 EUR   +5.08%
09/28European ADRs Move Higher in Wednesday Trading
MT
09/26European ADRs Decline in Monday Trading
MT
09/23European ADRs Fall in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ERYTECH PHARMA S.A.
09/12ERYTECH Provides Business and Financial Update for the First Half of 2022
GL
08/25Erytech Pharma S A : ▪ERYTECH to stop further plans to pursue a BLA submission seeki..
PU
08/24ERYTECH Provides Regulatory Update
GL
08/24ERYTECH Provides Regulatory Update
AQ
06/27Erytech's combined shareholders meeting on june 24, 2022
AQ
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
GL
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
AQ
05/25Erytech Pharma S A : Announces the Availability of the Documents for its Annual General Me..
PU
05/24ERYTECH Announces the Availability of the Documents for its Annual General Meeting to b..
GL
05/24ERYTECH Announces the Availability of the Documents for its Annual General Meeting to b..
AQ
05/18Erytech to present at the h.c. wainwright global investment conference
AQ
05/17ERYTECH to Present at the H.C. Wainwright Global Investment Conference
GL
05/17ERYTECH to Present at the H.C. Wainwright Global Investment Conference
AQ
05/12ERYTECH Provides Business and Financial Update for the First Quarter of 2022
GL
05/12ERYTECH Provides Business and Financial Update for the First Quarter of 2022
AQ
04/28ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report..
GL
04/28ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report..
AQ
04/28Erytech Pharma S A : ASSET PURCHASE AGREEMENT - Form 6-K
PU
04/26ERYTECH SELLS U.S. MANUFACTURING FACILITY AND ENTERS LONG-TERM SUPPLY AGREEMENT WITH CA..
AQ
04/25Erytech Pharma S A : Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreeme..
PU
04/25ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Ca..
AQ
04/06ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hyper..
AQ
04/04ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red..
AQ
03/28ERYTECH to Participate in the Upcoming April Investor Conferences
AQ
03/15Erytech Pharma S A : Provides Business and Financial Update for the Fourth Quarter and Ful..
PU
03/14Erytech provides business and financial update for the fourth quarter and full year 202..
AQ
03/11Erytech Pharma S A : Provides Business and Financial Update for the Fourth Quarter and Ful..
PU
02/10Erytech Pharma S A : Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases..
PU
02/08ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
AQ
01/27Erytech Pharma S A : ▪Interim results from the Phase 1 rESPECT trial of eryaspase pl..
PU
01/25Erytech announces presentation of results of two clinical trials of eryaspase in pancre..
AQ
01/24ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Panc..
AQ
01/03ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
AQ
2021Erytech Pharma S A : ANNOUNCES PRESENTATION OF RESULTS OF EXPANDED ACCESS PROGRAM IN ALL A..
PU
2021Erytech announces $7.85 million registered direct offering
AQ
2021ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH..
AQ
2021Erytech Pharma S A : Secures US Patent Directed to Sequential Use of Methioninase & Aspara..
PU
2021ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase aga..
AQ
2021ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
AQ
2021ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematolo..
GL
2021ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
AQ
2021Erytech Pharma S A : ▪The prespecified subgroup of patients treated with eryaspase a..
PU
2021Erytech Pharma S A : Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patien..
AQ
2021Erytech Pharma S A : Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator S..
PU
2021Erytech Pharma S A : Announces maximum tolerated dose declared in a phase 1 investigator s..
AQ
2021Erytech Pharma S A : Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator S..
AQ
2021Erytech Pharma S A : to Participate in the HealthTech Innovation Days (HTID) by France Bio..
AQ
2021Erytech Pharma S A : Announces the Availability of its Half-Year Financial Report 2021
AQ
2021Erytech Pharma S A : ▪TRYbeCA-1, Phase 3 trial of eryaspase in second-line metastati..
PU
2021Erytech Pharma S A : Provides Business Update and Reports Financial Results for the First ..
AQ
2021Erytech Pharma S A : I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL..
PU
2021Erytech Pharma S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
PU
2021Erytech Pharma S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
AQ
2021Erytech Pharma S A : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
GL
2021Erytech Pharma S A : Webinar on Eryaspase in Pancreatic Cancer (September 1, 2021)
PU
2021Erytech Pharma S A : to Participate in the Citi 16th Annual BioPharma Conference
GL
2021Erytech Pharma S A : Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
GL
2021Erytech Pharma S A : ▪Fast Track designation for eryaspase underscores the need for ..
PU
2021Erytech Pharma S A : Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensiti..
GL
2021Erytech Pharma S A : To participate in the btig virtual biotechnology conference
AQ
2021Erytech Pharma S A : to Participate in the BTIG Virtual Biotechnology Conference
AQ
2021Erytech Pharma S A : Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Pati..
PU
2021Erytech Pharma S A : Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Pati..
PU
2021Erytech Pharma S A : Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Pati..
GL
2021Erytech Pharma S A : REPORT - ERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021 (F..
PU
2021Erytech Pharma S A : Report - Erytech's Combined Shareholders' Meeting on June 25, 2021
AQ
2021Erytech Pharma S A : Report - Erytech's Combined Shareholders' Meeting on June 25, 2021
GL
2021Erytech Pharma : to Participate in Upcoming Virtual Investor Conferences in June
GL
2021Erytech Pharma : Availability of the preparatory documents for the Shareholders' Meeting (..
PU
2021Erytech Pharma : Provides Business Update and Reports Financial Results for the First Quar..
PU
2021Erytech Pharma : Provides business update and reports financial results for the first quar..
AQ
2021Erytech Pharma : Provides Business Update and Reports Financial Results for the First Quar..
GL
2021Erytech Pharma : Registered Direct Offering
PU
2021Erytech Pharma : Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2..
PU
2021Erytech Pharma : Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2..
GL
1  2  3  4Next
Upcoming event on ERYTECH PHARMA S.A.